Investment Thesis
Invivyd is a pre-commercial biotech company burning $41.7M annually against only $13.7M revenue, resulting in -301% net margins and negative free cash flow of -$42.4M. While the strong balance sheet ($184.2M cash, no debt) provides ~4.4 years of runway, the company faces fundamental profitability challenges with revenue insufficient to support current operating expenses until achieving significant commercialization.
Strengths
- Strong balance sheet with $184.2M cash and zero debt, providing financial flexibility
- Excellent liquidity ratios (Current: 6.47x, Quick: 6.32x) ensuring near-term solvency
- Revenue growing rapidly at +110.5% YoY, indicating early product-market traction
Risks
- Severe unprofitability with -301% net margin and operating losses of -$43.1M
- Negative operating cash flow of -$41.7M annually with free cash flow of -$42.4M
- Revenue base of $13.7M is minimal relative to burn rate; profitability timeline unclear
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway sustainability
- Revenue growth acceleration and gross margin development
- Path to operating profitability and clinical/commercialization milestones
Financial Metrics
Revenue
13.7M
Net Income
-41.4M
EPS (Diluted)
$-0.13
Free Cash Flow
-42.4M
Total Assets
241.7M
Cash
184.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-313.9%
Net Margin
-301.2%
ROE
-20.4%
ROA
-17.1%
FCF Margin
-308.8%
Balance Sheet & Liquidity
Current Ratio
6.47x
Quick Ratio
6.32x
Debt/Equity
0.00x
Debt/Assets
16.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:27:57.020113 |
Data as of: 2026-03-31 |
Powered by Claude AI